Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was $5.53M, compared with -$296K a year earlier. Trailing-twelve-month financing cash flow was $94.16M. Over 3 fiscal years it compounded at -5.1% a year.
Context
- Financing cash flow amounted to 263.8% of revenue in FY2025, down 842.0 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $5.53M or moves back toward the trailing-twelve-month quarterly average of $23.54M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 88.33M USD
- Year-over-year change
- +202.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.33M | +202.8% |
| FY2024 | 2024-12-31 | 29.17M | -36.9% |
| FY2023 | 2023-12-31 | 46.22M | -55.2% |
| FY2022 | 2022-12-31 | 103.26M | +2686.0% |
| FY2021 | 2021-12-31 | (3.99M) | — |
Financing Cash Flow vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +226.3% is the 5th highest of 11, against a peer median of +54.6%.
- Financing cash flow amounts to 287.7% of revenue for OBIO, versus a peer median of 266.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €232M EUR | +59.4% | +84.0% | 5175.1% | |
| LTM Mar 2026 | $215.52M USD | +89700.8% | +652.5% | 385.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $122.33M USD | +380.3% | +92.7% | — |
| LTM Mar 2026 | $94.16M USD | +226.3% | -5.1% | 287.7% | |
| LTM Mar 2026 | $82.13M USD | -42.0% | — | — | |
| LTM Mar 2026 | $57.73M USD | +12.7% | +11.7% | 25658.2% | |
| LTM Mar 2026 | $42.1M USD | +263.6% | — | 60.8% | |
| LTM Mar 2026 | $24.66M USD | +9371.4% | +212.3% | 147.5% | |
| LTM Mar 2026 | $15.99M USD | -76.2% | — | 27094.9% | |
| LTM Mar 2026 | $7.05M USD | +49.8% | +31.2% | 62.9% | |
| LTM Mar 2026 | $569K USD | -68.7% | +48.1% | 4.1% | |
| Peer median (excluding OBIO) | — | +54.6% | +84.0% | 266.6% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| Deferred Income Tax | 288K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 302K | 3.41M | 7.63M | 10.62M | 11.98M |
| Change in Working Capital | 2.6M | (451K) | (3.31M) | (765K) | (10.37M) |
| Accounts Receivables | 47K | 25K | (3K) | 22K | (3K) |
| Inventory | 1K | (208K) | 131K | (28K) | (137K) |
| Accounts Payables | 1.08M | 0 | 145K | 2.97M | 0 |
| Other Working Capital | 1.47M | (268K) | (3.58M) | (3.73M) | (10.23M) |
| Other Non-Cash Items | 217K | 1.14M | (1.61M) | 308K | 1.81M |
| Operating Cash Flow | (19.43M) | (29.29M) | (46.13M) | (50.56M) | (48.96M) |
| Capital Expenditures | (274K) | (591K) | (78K) | (289K) | (489K) |
| Acquisitions (Net) | (13.29M) | 0 | 0 | (602K) | 0 |
| Purchases of Investments | (213K) | (63.53M) | (142.03M) | (72.65M) | (76.31M) |
| Sales of Investments | 13.5M | 0 | 152.8M | 86.63M | 49.86M |
| Other Investing Activities | 13.29M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 13.02M | (64.12M) | 10.69M | 13.09M | (26.94M) |
| Debt Repayment | (4M) | 3.55M | (10.85M) | 15M | 17.91M |
| Common Stock Issued | 7K | 109.83M | 254K | 15.04M | 71.97M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7K | (10.13M) | 56.81M | (864K) | (1.55M) |
| Financing Cash Flow | (3.99M) | 103.26M | 46.22M | 29.17M | 88.33M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.41M) | 9.85M | 10.78M | (8.3M) | 12.43M |
| Free Cash Flow | (19.7M) | (29.88M) | (46.21M) | (50.85M) | (49.45M) |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.